4wi7
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | ''' | + | ==Structural mapping of the human IgG1 binding site for FcRn: hu3S193 Fc mutation H435A== |
| - | + | <StructureSection load='4wi7' size='340' side='right' caption='[[4wi7]], [[Resolution|resolution]] 1.90Å' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[4wi7]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4WI7 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4WI7 FirstGlance]. <br> | |
| - | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | |
| - | + | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4wi2|4wi2]], [[4wi3|4wi3]], [[4wi4|4wi4]], [[4wi5|4wi5]], [[4wi6|4wi6]], [[4wi8|4wi8]], [[4wi9|4wi9]]</td></tr> | |
| - | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4wi7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4wi7 OCA], [http://pdbe.org/4wi7 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4wi7 RCSB], [http://www.ebi.ac.uk/pdbsum/4wi7 PDBsum]</span></td></tr> | |
| - | [[ | + | </table> |
| - | [[ | + | == Disease == |
| - | [[Category: | + | [[http://www.uniprot.org/uniprot/IGHG1_HUMAN IGHG1_HUMAN]] Defects in IGHG1 are a cause of multiple myeloma (MM) [MIM:[http://omim.org/entry/254500 254500]]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving IGHG1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus. Translocation t(11;14)(q13;q32) with CCND1; translocation t(4;14)(p16.3;q32.3) with FGFR3; translocation t(6;14)(p25;q32) with IRF4. |
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Burvenich, I J.G]] | ||
[[Category: Farrugia, W]] | [[Category: Farrugia, W]] | ||
| - | [[Category: | + | [[Category: Ramsland, P A]] |
| + | [[Category: Scott, A M]] | ||
| + | [[Category: Fcrn binding site]] | ||
| + | [[Category: Human igg1]] | ||
| + | [[Category: Immune system]] | ||
| + | [[Category: Therapeutic antibody]] | ||
Revision as of 14:40, 30 September 2015
Structural mapping of the human IgG1 binding site for FcRn: hu3S193 Fc mutation H435A
| |||||||||||
